Lymphokinetic monitoring of a liver transplant recipient treated with OKT3.
Orthotopic liver transplantation was performed on a 48-year-old female patient with end-stage liver disease due to primary biliary cirrhosis. A course of OKT3 (5 mg/kg intravenously for 14 days) was given as immunosuppressive therapy. Lymphocyte population, T lymphocyte subsets and the lymphokine level in the peripheral blood were serially measured. Total T cells disappeared in the peripheral circulation within 10 minutes after an injection of OKT3. Helper T cells and suppressor T cells were also suppressed during the course of treatment. The ratio of T4/T8 declined from 2.5 to around 1.3. The serum interleukin-2 and the interleukin-2 receptor did not change markedly during treatment. The serum neopterin level increased after discontinuation of OKT3. The anti-mouse OKT3 antibody increased after the ninth day of OKT3 treatment. OKT3 showed potent T cell suppressive activity.
Lee
P H
PH
Department of Surgery, College of Medicine, National Taiwan University, Taipei, R.O.C.
Hu
R H
RH
Lai
H S
HS
Lai
M Y
MY
Tzeng
S S
SS
Lee
C S
CS
Chen
K M
KM
D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000097:blood; D008099:Liver / Q000503:physiopathology; D016031:Liver Transplantation; D008214:Lymphocytes / Q000276:immunology*; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000276:immunology / Q000627:therapeutic use*; D015375:Receptors, Interleukin-2 / Q000032:analysis
D007376:Interleukin-2; D016853:Muromonab-CD3; D015375:Receptors, Interleukin-2